placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Restless Legs Syndrome

Conditions

Restless Legs Syndrome

Trial Timeline

Apr 1, 2008 → Jan 1, 2009

About placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin

placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin is a phase 2 stage product being developed by Pfizer for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00676403. Target conditions include Restless Legs Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00676403Phase 2Completed

Competing Products

20 competing products in Restless Legs Syndrome

See all competitors
ProductCompanyStageHype Score
Gabapentin enacarbilAstellas PharmaApproved
85
ASP8825Astellas PharmaPhase 3
77
RegniteAstellas PharmaPre-clinical
23
ASP8825 + PlaceboAstellas PharmaPhase 2
52
Placebo + Gabapentin enacarbilAstellas PharmaApproved
85
Apomorphine Sublingual Film + PlaceboSumitomo PharmaApproved
85
SuvorexantMerckApproved
85
CabergolinePfizerPhase 3
76
Placebo + pregabalin + pregabalinPfizerPhase 3
76
pregabalin + placebo + pramipexolePfizerPhase 3
76
placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexolPfizerPhase 3
76
cabergoline + levodopaPfizerPhase 3
76
RotigotineUCBPhase 3
74
Neupro®UCBPre-clinical
20
Rotigotine Nasal SprayUCBPhase 2
49
RotigotineUCBPhase 3
74
Levetiracetam (Keppra)UCBPhase 2
49
Rotigotine + PlaceboUCBApproved
82
RotigotineUCBPhase 2
49
RotigotineUCBPhase 3
74